Molsidomine Biogaran (Molsidomine)

Molsidomine is indicated for conditions involving myocardial oxygen demand and coronary blood flow.

• Stable angina pectoris: reduces frequency and severity of angina attacks by improving coronary perfusion.
• Chronic stable angina: helps maintain exercise tolerance and decreases episodes of chest pain during daily activities.
• Angina pectoris (general): provides symptomatic relief through vasodilation and reduced cardiac workload.

• Molsidomine is a prodrug that is metabolized to l‑mosliden, which spontaneously releases nitroxyl (HNO). The nitroxyl donor activates soluble guanylate cyclase, increasing cyclic GMP levels in vascular smooth muscle. Elevated cGMP leads to relaxation of arterial and venous vessels, producing vasodilation, lowering systemic vascular resistance, and decreasing both cardiac preload and afterload, thereby alleviating myocardial oxygen demand.

Molsidomine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warm sensation with facial redness.
• Dizziness or light‑headedness, especially on standing.
• Nausea or mild gastrointestinal discomfort.
• Hypotension: modest reduction in blood pressure.
• Fatigue: feeling of reduced energy.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Allergic reactions: rash, pruritus, or angioedema.
• Myocardial infarction: rare but reported in susceptible individuals.
• Arrhythmias: irregular heart rhythms in high‑risk patients.
• Syncope: fainting episodes due to sudden blood pressure fall.
• Hepatic dysfunction: abnormal liver enzymes in isolated cases.

Before initiating therapy with Molsidomine, clinicians should consider several safety aspects.

• Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension.
• Hepatic impairment: use cautiously, adjust dose if liver function is compromised.
• Concomitant nitrates: avoid co‑administration due to additive vasodilatory effect.
• Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk.
• Elderly patients: start at lower dose and titrate slowly.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Molsidomine can interact with other agents that influence vascular tone or blood pressure.

Major Interactions (Avoid)

• Nitrate preparations (e.g., nitroglycerin): risk of profound hypotension.
• Phosphodiesterase‑5 inhibitors (e.g., sildenafil): additive vasodilatory effect.
• Other nitric‑oxide donors: may cause severe blood pressure drops.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs (ACE inhibitors, ARBs, beta‑blockers): monitor for additive blood pressure reduction.
• Diuretics: may enhance orthostatic hypotension.
• Antiplatelet agents: watch for increased bleeding tendency.
• CYP450 modulators: may alter molsidomine metabolism, requiring dose adjustment.